TEMHIGH SIGNALFINANCIAL10-K

TEM achieved massive financial transformation with 772% stockholders equity growth, 83% revenue increase, and dramatic loss reduction while significantly expanding its healthcare data network infrastructure.

The company has undergone a substantial business transformation, moving from near-insolvency with negative $56.3M equity to a robust $491.3M position, suggesting either major capital raising, debt restructuring, or operational turnaround. The simultaneous 83% revenue growth and 65% improvement in net losses indicates the company has achieved significant scale while dramatically improving operational efficiency.

Comparing 2026-02-24 vs 2025-02-24View on EDGAR →
FINANCIAL ANALYSIS

TEM experienced explosive growth across all major financial metrics, with total assets growing 146% to $2.3B and revenue increasing 83% to $1.3B, while dramatically improving profitability by reducing net losses from $705.8M to $245.0M. The 772% surge in stockholders equity from $56.3M to $491.3M represents a complete financial transformation, likely through major capital infusion or debt conversion. This comprehensive improvement across revenue growth, loss reduction, and balance sheet strength signals a company that has successfully scaled operations while achieving meaningful progress toward profitability.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+772.1%
$56.3M$491.3M

Equity base grew 772.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+145.6%
$926.1M$2.3B

Asset base grew 145.6% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+105.1%
$869.8M$1.8B

Liabilities grew 105.1% — significant increase in debt or obligations, assess impact on financial flexibility.

Accounts Receivable
Balance Sheet
+101%
$154.8M$311.2M

Receivables surged 101% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+83.4%
$693.4M$1.3B

Strong top-line growth of 83.4% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+77.4%
$341.0M$604.8M

Cash position surged 77.4% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+74.8%
$667.6M$1.2B

Current assets grew 74.8% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
+65.3%
-$705.8M-$245.0M

Net income grew 65.3% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+63.4%
-$691.1M-$252.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+34.7%
$38.4M$51.7M

Inventory surged 34.7% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-24
ADDED
As of February 20, 2026, there were 173,729,901 shares of Class A common stock and 5,043,789 shares of Class B common stock, each with a par value of $0.0001 per share, outstanding.
Our Platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through more than 700 unique data connections, many of which supply us with complex multimodal data in near real time, across more than 5,000 healthcare institution sites that order our products and services.
Our products are organized under two product lines, Diagnostics , which comprises our Oncology and Hereditary testing businesses, among others, and Data and applications , which includes, our Insights, Next, Trials and Algos businesses, among others .
Our Data and applications product line facilitates drug discovery and development for life sciences companies through multiple products, including, among other things, Insights, Trials, Next and Algos.
Our Trials product leverages the broad network of physicians we work with in oncology to provide clinical trial support for pharmaceutical companies that are looking to reach hard-to-find and underserved patient populations.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were 167,168,911 shares of Class A common stock and 5,043,789 shares of Class B common stock, each with a par value of $0.0001 per share, outstanding.
3 Our Platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through approximately 700 unique data connections, many of which supply us with complex multimodal data in near real time, across approximately 3,000 healthcare institutions that order our products and services.
Our products are organized under three product lines, Genomics , Data , and AI Applications or Algos.
Our Data and Services product line facilitates drug discovery and development for life sciences companies through two primary products, Insights and Trials.
Our second product within our Data and Services product line, Trials , leverages the broad network of physicians we work with in oncology to provide clinical trial support for pharmaceutical companies that are looking to reach hard-to-find and underserved patient populations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →